alpha-aminopyridine has been researched along with apremilast in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Del Pino-Montes, J; Gómez-Castro, S; Hidalgo, C; López, R; Montilla Morales, C; Sánchez, M | 1 |
| Gavaldà, A; Roberts, RS | 1 |
| Song, SD; Tang, HF | 1 |
| Bogdanos, DP; Mavropoulos, A; Sakkas, LI | 1 |
| Kataoka, S; Nakajima, K; Sano, S; Takaishi, M | 1 |
| Shah, CA | 1 |
4 review(s) available for alpha-aminopyridine and apremilast
| Article | Year |
|---|---|
[New therapeutic targets in psoriatic arthritis].
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antirheumatic Agents; Arthritis, Psoriatic; Bone Remodeling; Clinical Trials, Phase III as Topic; Cyclic AMP; Cytokines; Denosumab; Disease Progression; Drug Resistance; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Janus Kinases; Lymphocyte Activation; Lymphocyte Depletion; Molecular Targeted Therapy; Morpholines; Oxazines; Phosphodiesterase 4 Inhibitors; Pyridines; Pyrimidines; T-Lymphocyte Subsets; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012).
Topics: Administration, Oral; Aminopyridines; Animals; Benzamides; Cyclopropanes; Drug Approval; Drug Delivery Systems; Drug Design; Drug Industry; Humans; Patents as Topic; Phosphodiesterase 4 Inhibitors; Thalidomide | 2013 |
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; Inflammation; Inflammatory Bowel Diseases; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sulfones; Thalidomide; Thiazoles | 2014 |
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Topics: Aminopyridines; Autoimmune Diseases; Benzamides; Boron Compounds; Cyclopropanes; Eye Diseases; Humans; Immunologic Factors; Intestinal Diseases; Phosphodiesterase 4 Inhibitors; Skin Diseases; Thalidomide | 2017 |
2 other study(ies) available for alpha-aminopyridine and apremilast
| Article | Year |
|---|---|
Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.
Topics: Aminopyridines; Benzamides; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cyclic AMP; Cyclopropanes; Down-Regulation; Humans; Inflammation Mediators; Interleukin-18; Interleukin-1alpha; Interleukin-8; Keratinocytes; MAP Kinase Signaling System; Phosphodiesterase 4 Inhibitors; Psoriasis; Thalidomide; Tumor Necrosis Factor-alpha | 2020 |
Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?
Topics: Adrenal Cortex Hormones; Aminopyridines; Animals; Anti-Inflammatory Agents; Benzamides; COVID-19 Drug Treatment; Cyclopropanes; Cytokine Release Syndrome; Cytokines; Humans; Immune System; Immunity, Innate; Inflammation; Models, Theoretical; Phosphodiesterase 4 Inhibitors; Risk; Steroids; Thalidomide | 2020 |